Protara Therapeutics, Inc. (TARA) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$2.39

From 52W high−68.32%

Volume118564.00

Market cap$141.53M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$2.39

From 52W high

−68.32%

Volume

118564.00

Market cap

$141.53M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.8x

P/E (TTM)

—

RSI (14)

34.9

MomentumView details →

1D Return

−0.62%

YTD Return

−55.26%

SummaryUpdated Jun 1, 2026

Protara Therapeutics, Inc. (NASDAQ:TARA) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in New York, New York. Originally incorporated as ArTara Therapeutics, Inc., the company changed its name to Protara Therapeutics in May 2020. The company focuses on identifying and advancing transformative therapies for the treatment of cancer and rare diseases, with a particular emphasis on developing innovative cell therapies and substrate replacement treatments for underserved patient populations.

Ask drillr about Protara Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.8x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.9x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−43.40%

ROA (TTM)

−39.76%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+16.05%

FCF YoY

−48.49%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+38.25%

EBITDA YoY

−31.04%

MomentumView details →

1D Return

−0.62%

YTD Return

−55.26%

1Y Return

−46.30%

RSI (14)

34.9

vs 50D SMA

−23.07%

vs 200D SMA

−47.27%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

10.97x

Quick Ratio

10.97x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.36

EPS Surprise

−10.53%

Beats (12Q)

8/12

Next Q EPS Est

−$0.37

Avg Surprise (4Q)

5.24%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−70.02M

Op. CF (TTM)

−66.13M

Next earningsNov 9, 2026 →

Latest newsMore news →

Protara Therapeutics reported a net loss of $21.7 million for Q2 2026, with research and development expenses of $17.0 million and general and administrative expenses of $6.4 million.86d ago

Similar companies

Veraxa Biotech Holding AGVRXA Compass Therapeutics, Inc.CMPX MacroGenics, Inc.MGNX NervGen Pharma Corp. Common stockNGEN Cue Biopharma, Inc.CUE Avidity Biosciences, Inc.RNA Find similar companies →

Latest newsMore news →

Protara Therapeutics, Inc. completed enrollment of 24 patients in the Phase 2b open-label dose-confirmation phase of its THRIVE-3 trial evaluating IV choline chloride in patients with intestinal failure dependent on parenteral support.20d ago Protara Therapeutics reported a net loss of $21.7 million for Q2 2026, with research and development expenses of $17.0 million and general and administrative expenses of $6.4 million.86d ago